AUXL Profile
Auxilium Pharmaceuticals, Inc. (AUXL) was a specialty biopharmaceutical company that focused on developing and marketing products for urology and sexual health. The company was based in the United States and was founded in 1999.
In 2015, Auxilium Pharmaceuticals was acquired by Endo International plc, a global specialty pharmaceutical company based in Dublin, Ireland. Under the terms of the acquisition, Endo paid $33.25 per share in cash for all outstanding shares of Auxilium, which represented a total transaction value of approximately $2.6 billion.
At the time of the acquisition, Auxilium Pharmaceuticals had a number of products on the market, including Xiaflex, which was approved by the U.S. Food and Drug Administration for the treatment of Dupuytren's contracture and Peyronie's disease. Additionally, the company had a number of other products in development, including treatments for overactive bladder and testosterone deficiency.
It's important to note that since my knowledge cutoff date of September 2021, there may have been updates or developments regarding Auxilium Pharmaceuticals and its products or acquisition by Endo International.
|
